Theravance Biopharma, Inc. filings document operating results, material events, governance matters, and portfolio disclosures for a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual financial updates, YUPELRI collaboration revenue, business updates, Regulation FD materials, and financial-condition disclosures tied to the company’s therapeutics business.
The filing record also covers product and intellectual-property matters, including a Hatch-Waxman settlement resolving ANDA patent litigation involving YUPELRI® (revefenacin) inhalation solution. Other disclosures address the ampreloxetine Phase 3 CYPRESS outcome, costs associated with organizational restructuring and program wind-down activities, annual general meeting voting matters, director elections, and proxy governance.
Theravance Biopharma (NASDAQ: TBPH) filed an 8-K disclosing that China’s NMPA approved YUPELRI (revefenacin), the first once-daily nebulized LAMA for COPD in China.
The decision triggers a $7.5 million one-time milestone payment from partner Viatris, expected in Q3 2025, and entitles Theravance to additional sales-based milestones and tiered royalties on Chinese net sales. Viatris will fund and manage all development and commercialization activities.
No other financial statements were furnished; the disclosure is limited to Item 8.01 and Exhibit 99.1.
Rick E. Winningham, CEO and Director of Theravance Biopharma, reported a significant insider transaction on June 23, 2025. The executive made a bona fide gift of 20,000 ordinary shares with no compensation received.
Following the transaction, Winningham's holdings include:
- 1,733,180 shares held directly
- 13,500 shares held as custodian
- 92,567 shares held in trust
The Form 4 filing indicates Winningham maintains substantial ownership in the company despite the gifted shares. The transaction was executed under regular conditions and was not part of a Rule 10b5-1 trading plan. The filing was completed through his attorney-in-fact, Brett A. Grimaud, on June 25, 2025.